Bellevue Group AG (BBN.SW) is an independent Swiss asset manager focused on specialized equity strategies in healthcare, small and mid-cap companies, and growth themes. The company offers a range of active investment products including healthcare solutions in biotech, medtech, thematic healthcare, global and regional healthcare funds; small and mid-cap equity strategies such as Bellevue Entrepreneur Europe Small; private markets investments via growth equity in SMEs; and recent launches like the AI Health Fund, Obesity Solutions Fund, and the first active healthcare ETF. It operates through boutique units including Bellevue Asset Management AG and provides services to institutional and private clients across Switzerland, Germany, the United Kingdom, Asia Pacific, and internationally, with assets under management around CHF 6.9 billion.
Founded in 1993 and headquartered in Zurich, Switzerland, Bellevue Group AG maintains offices in Zug, New York, Frankfurt, London, Singapore, and Madrid to support its global reach. The firm targets fast-growing sectors requiring active management, emphasizing entrepreneurial investments and owner-operated companies in regions like DACH (Germany, Austria, Switzerland).
Recent developments include the launch of its first active ETF focused on healthcare stocks in September 2025; recruitment of two experienced healthcare analysts in November 2025 to bolster research; sale of private equity boutique adbodmer AG via management buy-out in October 2025 to sharpen its business model; establishment of a Singapore subsidiary in January 2025 to expand in Asia; appointment of a new Investment Manager for Bellevue Healthcare Trust and streamlining of UK activities in October 2025; relocation to its founding location in Zurich's Bellevue district in November 2024; and leadership changes such as Gebhard Giselbrecht as CEO in 2023 with further executive adjustments in 2025.